Single Center Experience with a 4-Week 177 Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer.

Jukka KemppainenAki KangasmäkiSimona MalaspinaBernd PapeJarno JalomäkiKalevi KairemoJuha KononenTimo Joensuu

Published in: Cancers (2022)

Lu-PSMA-617 treatment in four-week intervals was safe and effective. Almost 60% of patients had a significant PSA response, which was associated with better OS. Pre-treatment PSA kinetics or staging PSMA PET/CT-derived parameters were not helpful in identifying treatment responders from non-responders; better biomarkers are needed to aid in patient selection.

Keyphrases

pet ct
prostate cancer
end stage renal disease
chronic kidney disease
lymph node
randomized controlled trial
computed tomography
newly diagnosed
peritoneal dialysis
replacement therapy
smoking cessation